Sugi Predict

Sugi Predict / Compounds / SCHEMBL1552396

SCHEMBL1552396

SCHEMBL1552396

CCOC(=O)c1sc(N)nc1CO

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ HPGD P15428 4/20 0.63
▸ HSD17B10 Q99714 3/20 0.57
▸ LMNA P02545 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPT P10636 5/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ FBP1 P09467 1/20 0.48
▸ GAA P10253 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ CDC7 O00311 1/20 0.46
▸ DBF4 Q9UBU7 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859765 0.90 ALDH1A1 (0.69) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL2082176 0.89 ALDH1A1 (0.67) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL2444986 0.86 ALDH1A1 (0.50) ALDH1A1CYP1A2HPGDHSD17B10KDM4E
SCHEMBL2823884 0.86 ALDH1A1 (0.63) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL2720641 0.86 ALDH1A1 (0.63) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL13125915 0.84 ALDH1A1 (0.61) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL3098533 0.84 ALDH1A1 (0.65) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL244752 0.83 ALDH1A1 (0.73) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL1921091 0.81 ALDH1A1 (0.49) ALDH1A1CYP1A2HPGDHSD17B10LMNA
SCHEMBL3119761 0.81 ALDH1A1 (1.00) ALDH1A1CYP1A2HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4735426-A1 HETEROAROMATIC DHODH INHIBITORS Immunic AG (DE) 2026-05-06 — — EP disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 — — US disclosed
WO-2025003402-A1 HETEROAROMATIC DHODH INHIBITORS IMMUNIC AG (DE) 2025-01-02 — — WO disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
US-20240043450-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2024-02-08 — — US disclosed
EP-4217347-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
CN-116194445-A New compounds 詹森药业有限公司 2023-05-30 — — CN disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 — — WO disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 — — WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 — — US disclosed
WO-2008068470-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS ASTRAZENECA AB (SE) 2008-06-12 — — WO disclosed
WO-2008068470-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS ASTRAZENECA AB (SE) 2008-06-12 — — WO disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 — — US disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 — — US disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 — — US disclosed
EP-1853586-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES AstraZeneca AB (SE) 2007-11-14 — — EP disclosed
WO-2006087543-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2006-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLQ, POLB, POLK ALDH1A1 1052/4885CYP1A2 118/4885HPGD 404/4885
US-20240043450-A1 NEW COMPOUND NLRP3, NLRP1, PYCARD ALDH1A1 1954/4885CYP1A2 1468/4885HPGD 2200/4885
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 ALDH1A1 840/4885CYP1A2 180/4885HPGD 2356/4885
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses POLA1, CTDSP1, SUB1 ALDH1A1 589/4885CYP1A2 212/4885HPGD 2974/4885
US-20080132546-A1 CHEMICAL COMPOUNDS MRPL21, NISCH, ABCB11 ALDH1A1 488/4885CYP1A2 41/4885HPGD 389/4885
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR ALDH1A1 243/4885CYP1A2 156/4885HPGD 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.